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INTRODUCTION 
 
Epilepsy describes a condition in which a person has recurrent seizures due to 
chronic underlying process. Epilepsy refers to a clinical phenomenon rather than a single 
disease entity, since there are many forms and causes of epilepsy.  
Traditionally, the diagnosis of epilepsy requires the occurrence of at least two 
unprovoked seizures which are 24 hours apart. Some clinicians diagnose epilepsy when 
one unprovoked seizure occurs in the setting of an interictal discharge. Seizures are the 
manifestation of abnormal hypersynchronous discharges of cortical neurons. The signs 
and symptoms of seizures depend on the cortical location of the epileptic discharges and 
the propagation pattern of the epileptic discharge in the brain. 
The causes of epilepsy may primary or secondary. Epilepsy is usually managed by 
neurologists or general practitioners. Treatment is symptomatic and similar whether the 
epilepsy is primary or secondary with usage of antiepileptic drug. 
Epilepsy is not a contraindication to pregnancy. Women with epilepsy can be 
reassured that having epilepsy should not prevent them from having children. However 
close medical care is essential and a multidisciplinary approach is recommended. 
Pregnancies in women with epilepsy are high risk and need careful management 
by both the medical and obstetric teams due to the increased incidence of complications 
and adverse outcomes of pregnancy. By the time a pregnant woman with epilepsy 
presents, the fetus is virtually fully formed and the opportunity for altering drug treatment 
has passed (Crawford P., 2002)6  
Majority of women with epilepsy will have normal and healthy infants. Effective 
pre-conceptional counseling and medical care is essential for the treatment of the 
pregnant women with epilepsy. Exposure to AED has been associated with two to three 
times increase in major malformations in infants exposed in utero as compared to the 
ordinary population. Managing epilepsy during pregnancy is a major therapeutic 
challenge, as the potential adverse effects of antiepileptic drugs on the fetus must be bal-
anced against the maternal and fetal risks associated with uncontrolled seizures (Torbjörn 
Tomson, Vilho Hiilesmaa, 2007 )18 
  It is very important that all women with pregnancies have a preconception 
evaluation done by a neurologist, when the need to continue AEDs or possibility of 
reducing AED load could be assessed (Thomas SV, 2011). 17. 
 
                      
EPILEPSY 
 
Epilepsy - (from the Ancient Greek epilēpsía) recognized from the dawn of history 
as ‘disease of lightening’ and it was correctly described by JH. Jackson little over a 
century ago. 
Epilepsy is a neurological disorder characterized by paroxysmal cerebral 
dysrhythmia, manifesting as brief episodes (seizures) of loss / impairment of 
consciousness, abnormal motor, sensory or psychiatric phenomena, with or without 
characteristic body movements (convulsions). 
Epilepsies have been classified as Generalized and Partial seizures. 
 Generalized seizures include: 
1) Generalized tonic-clonic seizures (GTCS / Grand mal, commonest) 
2) Absence seizure (petit mal, common in children) 
3) Atonic seizures (Akinetic epilepsy) 
4) Myoclonic seizures (shock like contraction of muscles) 
5) Infantile spasms (probably not a form of epilepsy) 
 
Partial seizures include: 
1) Simple partial seizures (SPS / Cortical focal epilepsy)  
2) Complex partial seizures (CPS / psychomotor / temporal lobe epilepsy)  
        - with or without secondary generalization. 
Generalized seizures: 
           These involve both brain hemispheres simultaneously and may be preceded by an 
aura before an abrupt loss of consciousness. There is strong hereditary component. In 
grandmal seizures, loss of consciousness is followed by tonic contraction of the muscles, 
rigid posturing and gradual relaxation. Return of consciousness is gradual and the patient 
may remain confused and disoriented for several hours. Absence seizures also called petit 
mal seizures, are form of generalized seizures that involve brief loss of consciousness 
without muscle activity and are characterized by immediate recovery of consciousness 
and orientation. 
Partial seizures: 
           These originate in one localized area of the brain and affect a corresponding 
neurological function. They are believed to result from trauma, abscess, tumors or 
perinatal factors, although specific lesion is rarely demonstrated. Simple motor seizures 
start in one region of the body and progress toward other ipsilateral areas of the body 
producing tonic and then clonic movements. 
           Simple seizures can affect sensory function or produce autonomic dysfunction or 
psychological changes. Consciousness is usually not lost and recovery is rapid. Partial 
seizures can secondarily generalize producing loss of consciousness and convulsions. 
Complex partial seizures also called temporal lobe or psychomotor seizures usually 
involve clouding of consciousness. 
Investigations  
           Epilepsy is one of the commonest neurological disorders in our country. Patients 
with epilepsy are investigated with EEG, CT and MRI scan.  
The Electroencephalograph (EEG) which records the electrical activity of the 
brain cells is helpful, when it is clearly abnormal. But 40-50% of patients with epilepsy 
have a normal single inter-ictal EEG. On the other hand, about 5% of non-epileptic 
patients may have non-specific EEG abnormalities. Despite its limitations, the EEG is a 
simple non-invasive and relatively inexpensive test that gives useful information if used 
judiciously and correlated with the clinical description of seizures. When abnormal, it is 
helpful in making a correct diagnosis of epilepsy and may even help in the choice of  
anti-epileptic drug therapy. 
 
Computed tomography (CT) scanning is helpful, especially where an underlying 
pathology is suspected as the cause of seizures. Magnetic resonance imaging (MRI) is 
now established to be a better and safer diagnostic modality than CT scanning for the 
detection of an epileptogenic focus or suspected brain abnormalities in patients with 
seizures.  
Causes of epilepsy 
            Most cases are primary (idiopathic) and some may be secondary to intracranial 
tumors, infection (tuberculoma, neurocysticercosis), ischemia, trauma. The diagnosis of 
idiopathic epilepsy is one of exclusion. 
 In practice, it is useful to consider the etiologies of seizures based on the age of 
the patient. During the neonatal period and early infancy, potential cause includes 
hypoxic-ischemic encephalopathy, congenital CNS malformations, CNS infection and 
metabolic disorders. The most common seizures arising in late infancy and early 
childhood are febrile seizures, which are seizures, associated with fevers but without 
evidence of CNS infection or other defined causes. Childhood mark the age at which 
many of the well-defined epilepsy syndromes present. Temporal lobe epilepsy usually 
present in childhood and may be related to mesial temporal lobe sclerosis. 
The period of adolescence and early adulthood is one of transition during which 
the idiopathic or genetically based epilepsy syndromes become less common, while 
epilepsies secondary to acquired CNS lesions begin to predominate. It may be associated 
with head trauma, CNS infections, brain tumors, and drug / alcohol withdrawal. The 
causes of seizures in older adults include cerebrovascular disease, cerebral tumors and 
degenerative diseases. 
Treatment of epilepsy  
Treatment is symptomatic and similar whether the epilepsy is primary or 
secondary. Varieties of antiepileptic drugs (AED) are in use like phenobarbitone, 
phenytoin, carbamazepine, valproic acid, ethosuximide, diazepam/clonazepam, 
lamotrigine and newer drugs like vigabatrin, topiramate & levetiracetam, with each drug 
having its own advantage and limitations. 
 
 
 
 
 
 
 
 
 
 
 
EPILEPSY  IN  PREGNANCY 
 
Pregnancy of women with known epilepsy refer to ‘Epilepsy in pregnancy’. The 
most common cause for seizures during pregnancy is pre-existing epilepsy, while new-
onset seizures in latter half of pregnancy or during the immediate postpartum period are 
most frequently caused by eclampsia. 
Some women with epilepsy may experience seizure only during pregnancy which 
is termed ‘gestational epilepsy’ such women would be seizure free between pregnancies. 
Another subgroup (Gestational onset Epilepsy) may have their first seizure during 
pregnancy and thereafter may continue to get spontaneous recurrent seizures (Charu 
Jandial., et al, 2007) 4. 
Epilepsy is the second common chronic neurological disorder complicating 
pregnancy after migraine (Chattopadhyay Nibedita., et al, 2008) 5. About 2.7 million 
women in India suffer from epilepsy, with 52% of them being in the reproductive age 
group (Thomas SV 2011) 17. Incidence of seizure disorder in women attending antenatal 
clinics is estimated to be 0.3-0.5% of all births. 5, 17  
 
 
 
Pregnancy in the woman who has epilepsy raises several concerns about the risk 
of adverse maternal and fetal outcomes, including the risk of more frequent seizures and 
the potential for antiepileptic drug-related teratogenicity (Martha j. Morrell -2002) 12.  
The cause of this teratogenicity could be due to direct drug toxicity, drug-induced 
folate deficiency or genetically determined lack of epoxide hydrolase or free radicals. 
The role of the hepatic mixed function oxidase system may be specially important in 
conferring teratogenic risk (Charu Jandial., et al, 2007) 4. 
The most important goal of therapy, both prenatally and during pregnancy, is to 
optimally control seizures. The drug selected for a patient should be determined by the 
type of seizure she has, using only a single drug if possible. 
Regarding the general management of epileptic women the first and foremost is to 
determine whether a woman of childbearing age requires antiepileptic drugs (Charu 
Jandial., et al, 2007) 4. If needed as far as possible monotherapy should be the aim.  Diet 
before conception should contain adequate amounts of folate.  Free or plasma levels of 
AEDs should be regularly checked and they need one antenatal ultrasonography to rule 
out congenital malformations.  
Polytherapy involving treatment with more than one AED also seems to be 
associated with an increased risk of birth defects compared with monotherapy (Battino., 
etal, 2007) 2. 
EFFECTS  OF  EPILEPSY  ON  PREGNANCY 
Both published and unpublished data indicate women who have epilepsy face a 
higher risk of pregnancy-related complications including hyperemesis, anemia, 
antepartum / postpartum hemorrhages, placental abruption, preeclampsia, premature birth 
and low birth weight baby.  Data on first trimester losses, premature rupture of 
membranes (PROM), operative vaginal delivery and caesarean section are inconclusive. 
Regarding fetus, increased incidence of intrauterine growth retardation (IUGR), 
cognitive dysfunction, microcephaly and perinatal mortality has been reported with 
increased incidence of congenital malformations (Page B. Pennell, 2002) 14. 
Women with epilepsy have a 4 to 8 percent chance of giving birth to a child with a 
major malformation, compared with 2 to 4 percent in the general population 
(Chattopadhyay Nibedita., et al, 2008) 5 (Martha j. Morrell -2002) 12. Although the 
maternal trait of epilepsy may predispose neonates to birth defects, a recent study 
suggests that the risk of birth defects is entirely associated with maternal use of 
antiepileptic drugs. 
Teratogenicity of main anticonvulsants (Charu Jandial., et al, 2007) 4 
1.   Phenobarbitone:   Probably no rise in malformation rate. 
2.   Phenytoin:   Orofacial clefts, congenital heart defects dysmorphic facial  
     features, fetal hydantoin syndrome. 
3.  Carbamazepine: Craniofacial defects, finger nail, hypoplasia, developmental  
     delay. 
4. Valproic acid: Neural tube defects. 
 
Malformations associated with exposure to the older antiepileptic drugs include 
cleft lip/palate and ventricular septal defect. Neural tube defects are associated with 
exposure to valproate and carbamazepine (Tegretol) at a frequency of 1 to 2 percent and 
0.5 to 1 percent, respectively (Martha j. Morrell, 2002)12. 
 Minor congenital anomalies affect 7 to 15 percent of infants exposed to 
antiepileptic drugs, which represents a twofold increase over that in the general 
population. These anomalies principally involve the face and digits, including 
hypertelorism, epicanthal folds, broad nasal bridge, elongated philtrum, distal digital, and 
nail bed hypoplasia (Chattopadhyay Nibedita., et al, 2008) 5  (Martha j. Morrell, 2002)12. 
There are several potential mechanisms for antiepileptic drug-mediated 
teratogenesis. The older generation of antiepileptic drugs generates free radical 
metabolites and induces folic acid deficiency (Martha j. Morrell, 2002)12. The risk of 
teratogenicity is significantly increased in women taking multiple antiepileptic drugs and 
in those on high doses of antiepileptic medication. The newer generation of antiepileptic 
drugs is not teratogenic in animals, but there is no sufficient data in human pregnancy. 
Epilepsy in pregnancy presents a unique challenge for both the mother and her 
baby. Managing epilepsy during pregnancy is a major therapeutic challenge, as the 
potential adverse effects of antiepileptic drugs on the fetus must be balanced against the 
maternal and fetal risks associated with uncontrolled seizures. 
 
EFFECTS  OF  PREGNANCY  ON  EPILEPSY 
 
 
 
 The effect of pregnancy on epilepsy are unpredictable and the seizure frequency 
may increase, decrease or may remain unchanged. Seizure remain unchanged in more 
than half of women, one third experience more frequent seizures and minority improved.  
 
Seizure frequency may increase due to, (Lara E. Jeha 2005) 11 
 - Enhanced metabolism & increased drug clearance associated with  
    pregnancy, resulting in decreased serum drug concentration.  
 - Increased volume distribution of the AED. 
 - Increased serum binding proteins.  
 - Decreased or non-compliance with medication.  
 - Factors which lower the threshold for seizures like sleep deprivation,  
    hormonal changes of pregnancy (high E), associated psychological      
    and emotional stress of pregnancy. 
 
Seizure frequency may decrease due to 
         -  Improved compliance with drug regimen in some patients. 
 
In some patients the seizure frequency may remain unchanged. 
 
 
 
 
AIM OF THE STUDY 
 
 
• To evaluate the effect of epilepsy on pregnancy regarding 
 the maternal and fetal outcome. 
 
• To evaluate the effect of pregnancy on epilepsy regarding 
 the frequency of seizure occurrence. 
 
 
 
 
 
  
 
 
 
 
REVIEW OF LITERATURE 
 
 (Thomas SV et al., 2001)16 in his study on Pregnancy in women with epilepsy 
followed up 85 women with epilepsy for reproductive functions under the registry of 
Kerala.  32 of them had completed the pregnancy. Pregnancy ended as spontaneous 
abortion in one patient. Nearly one third required cesarean section. Majority (87.5%) had 
term babies and three (10.7%) babies had birth asphyxia. Six babies (21.4%) had low 
birth weight. Congenital malformations were detected in four cases (12.5%). The risk of 
malformation was significantly greater (p<0.05) when the mother had generalized 
epilepsy. Majority of women with epilepsy had safe pregnancy and childbirth without 
any aggravation of epilepsy. 
(Page B. Pennell., 2002)14 in his article in seminars in neurology about Maternal 
and Fetal outcomes in pregnant women with epilepsy has summarized epilepsy is 
associated with increased obstetric risks and increased adverse neonatal outcomes. Prior 
to conception, folic acid should be administered and the antiepileptic drug (AED) 
regimen should be optimized, preferably using AED monotherapy. Folate 
supplementation should begin prior to conception and is crucial during the first 30 days 
of gestation. Periodic monitoring of total and free AED levels is recommended.   Prenatal 
screening should be offered. Careful planning and management of any pregnancy in 
women with epilepsy are essential to increase the likelihood of a healthy outcome for the 
mother and infant. 
(Crawford P., 2002 )6 in his study on Epilepsy and pregnancy had indicated that  
all major anticonvulsant drugs are teratogenic but the main risk to the developing fetus 
appears to be when the mother is on polytherapy especially if sodium valproate forms 
part of the combination. Folate supplements (5 mg) before conception are advisable.  He 
also denoted  that there appears to be a minor but significant increased risk of maternal 
complications such as hyperemesis gravidarum, pre-eclampsia and eclampsia, vaginal 
bleeding and premature labour. In the majority of women seizure control will not alter 
during pregnancy. There is an increased risk of prematurity (9-11%), stillbirth, neonatal 
and perinatal death, haemorrhagic disease of the newborn, low Apgar scores and low 
birth weight (7-10%). 
In a retrospective case-control study done by (P. Goel, L. Devi et al., 2006) 9for 
Maternal and Perinatal Outcome in Pregnancy with Epilepsy, they had concluded, though 
significant proportion of the epileptic patients had seizures during pregnancy, the 
maternal and fetal outcome was similar in both the groups. There was no statistically 
significant difference in the pregnancy related complications such as pregnancy induced 
hypertension (PIH), eclampsia, abruptio placenta, placenta previa, anemia and gestational 
diabetes mellitus (GDM) in both the groups. Mean period of gestation and rate of 
caesarean section was similar in both the groups. Prematurity was observed in 21.6% 
cases and 17.6% in controls.  
 
Fetal outcomes (APGAR score, birth weight, still births, neonatal death and 
congenital malformation) were also similar in the two groups. 75% of the patient in study 
group were on monotherapy. Fourteen patients had seizure during pregnancy, but there 
were no maternal complications. 
(Battino, Dina; Tomson, Torbjörn., 2007 )18 in their neurology article for 
Management of Epilepsy during Pregnancy had stated that  the teratogenic effects of 
valproic acid appear to be dose dependent, with higher risks at dosage levels >1000 
mg/day. Polytherapy involving treatment with more than one AED also seems to be 
associated with an increased risk of birth defects compared with monotherapy. They 
advised to use the appropriate AED as monotherapy in the lowest effective dosage 
throughout pregnancy in such a way that seizures are avoided but with minimized risks to 
the fetus and to avoid valproic acid if possible. Any major change in the treatment of a 
woman with epilepsy should ideally be completed before conception and they 
recommended regular monitoring of drug concentrations during pregnancy. 
A prospective study done by (Chattopadhyay Nibedita et al., 2008)5  for Feto-
maternal outcome in pregnancy with epilepsy,  had stated that out of  43 pregnant women 
they studied, fetal loss and major malformations were observed in 4.65% cases each. Out 
of the 41 live born infants major congenital malformations were observed in two babies 
and minor anomalies in three. 
A population-based cohort study done by (Borthen I et al., 2010)3 for delivery 
outcome of women with epilepsy had concluded that pregnant women with epilepsy have 
a low complication rate. However they have a slightly increased risk of induction, 
caesarean section and postpartum haemorrhage. These rates were even higher for women 
with epilepsy and antiepileptic drug use. In addition, the risk of an Apgar score < 7 was 
higher. He also suggested it is not possible to ascertain on the basis of this study whether 
this is a result of more severe epilepsy or antiepileptic drug use. 
(Sanjeev V Thomas, 2011)17 in his article of Managing epilepsy in pregnancy has 
stated about 10% of the babies in pregnant women with epilepsy may have major 
congenital malformations and most adverse outcomes are related to antiepileptic drugs 
(AEDs).  Polytherapy, high dose of any AED, traditional AEDs like phenobarbitone 
/sodium valproate are probably associated with higher risk fetal complications.  They had 
also advised it is important that all women with epilepsy should have a preconception 
evaluation done by a neurologist regarding the AED and to take folic acid 5 mg daily 
during preconception period and pregnancy. They should undergo a detailed screening 
for fetal malformations between 12 and 18 weeks of pregnancy.   
 
                     
MATERIALS AND METHODS 
 
 
This prospective study on epilepsy complicating pregnancy was conducted in 
Government Rajaji hospital (GRH), Madurai from June 2010 to May 2011. Permission 
from Ethical Committee of the hospital was obtained for research purpose. 
All consecutive epileptic patients admitted in department of Obstetrics and 
Gynecology, Government Rajaji Hospital, Madurai, were recruited for this study with 
fulfillment of following criteria. 
 
Inclusion criteria   
 
1. All pregnant women with history of epilepsy  
2. Both primigravida and multigravida 
3. Both booked and unbooked cases 
4. All type of seizure disorder (GTCS, Partial)   
5. Patients on regular or irregular intake of AEDs 
6. Patients on Monotherapy or polytherapy of AEDs 
7. Patients not on AEDs as per neurologist advice 
8. Patients who discontinued AEDs by themselves  
 
  
Exclusion criteria   
 
1. Eclamptic patients      
2.  Postpartum seizure (including Eclampsia, CVT) 
3. Cases of metabolic encephalopathy / drug toxicity 
4.   Psychogenic causes    
 
Pregnant women with history of epilepsy, recruited for this study were enquired 
with detailed history regarding their age, booking status, gravida and details of menstrual 
history to arrive expected date of delivery. Their detail obstetric history was recorded 
especially about their performance during previous delivery. History of imminent 
symptoms like headache, nausea, vomiting, blurring of vision, epigastric pain and 
oliguria was obtained.  History of other obstetrical complications like oligohydramnios, 
PIH, antepartum hemorrhage was also obtained. 
 Past history regarding the age of onset of seizures, type of seizure, period at 
which the patient had last seizure, disease free interval and history of status epilepticus 
was obtained. The details of antiepileptic drugs, type and duration of therapy, regular or 
irregular intake of AED and folic acid intake was obtained.  
 
Presence of other medical conditions like diabetes mellitus, hypertension, 
tuberculosis, heart disease and renal disease were elicited. Detail neurological history to 
rule out CNS lesion, trauma, infection, and tumor and drug intake was elicited. 
General and systemic examination including thorough CNS examination, per 
abdominal and per vaginal examination was done for all patients. Blood pressure 
measurement and fundus examination was also done. Neurologist opinion was obtained 
for all cases. 
Investigations like HB%, urine (Alb, sugar) blood urea, sugar, serum creatinine, 
serum uric acid, serum electrolytes, liver function tests and platelet count were done. 
EEG was taken for all cases. 
Ultrasonographic examination was done for gestational age assessment, liquor 
status, IUGR and to rule out congenital anomalies.   
 All pregnant epileptic women were admitted in ward before the expected date of 
delivery and evaluated for epilepsy and their treatment was individualized according to 
neurologist advice. As the patient gets into labour, they were monitored carefully during 
labour with partogram and the mode of delivery in all patients was recorded. Caesarean 
section was done for obstetric indications.   
Maternal outcome was evaluated by the occurrence of seizures during labour or 
postpartum and for other obstetric complications like oligohydramnios, PIH, antepartum 
haemorrhage, postpartum haemorrhage.  
Fetal outcome was obtained by the Birth weight of the baby, Apgar scoring and 
evidence of any congenital anomalies. Apgar scoring was recorded for 1 and 5 minutes. 
Pediatric opinion was obtained for all neonates. Neonate with prematurity, low Apgar 
scores, IUGR, and anomalies were admitted in Neonatal intensive care units. Head 
circumference measurement was done for all babies. 
All delivered epileptic patients were observed in the labour ward for period of 48 
hours following delivery. Postnatally all patients were subjected to CT to rule out other 
causes. AEDs were continued postnatally and patients were discharged after obtaining 
neurologist advice. Postnatal counseling done to continue the AEDs. 
Statistical Tools   
 
          The information collected regarding all the selected cases were recorded in a 
Master Chart.  
Data analysis was done with the help of computer using Epidemiological Information 
Package (EPI 2010) developed by Centre for Disease Control, Atlanta. 
Using this software range, frequencies, percentages, means, standard deviations, chi 
square and ‘p’ values were calculated.  
Kruskul Wallis chi-square test was used to test the significance of difference 
between quantitative variables.  
A 'p' value less than 0.05 is taken to denote significant relationship. 
REPRESENTATIVE CASES 
 
 
Case: 1 
                  
          
 
20 year old primigravida with GTCS, last fit 4 years back. She had abnormal EEG and 
normal CT.   She was on regular intake of T. Phenytoin 2Hs and folic acid and she  
delivered a term live male baby with birth weight of 2.7 kg with good Apgar without any 
maternal complication   
 
 
 
 
Case 2: 
 
                   
         
 
25 year old primigravida with GTCS and disease free interval for 2 months. She had normal 
EEG and normal CT. She was on regular intake of T. carbamazepine 2-1-2. LSCS done for failed 
induction with fetal distress. New born Birth weight was 3 kg with good Apgar score.  
 
 
Case 3: 
 
                                I        
                                           
     
 
20 year old primigravida with GTCS type of seizure and disease free interval of 12 years. EEG 
was abnormal and CT showed calcified granuloma. She was on T. Phenytoin 2 HS. She 
delivered a baby with IUGR. BW was 2.5 Kg with Good Apgar score.   
 
 
 
 
Case 4:   
 
                     
                      
 
30 year old multigravida (G3 P2 L1) with last fit 6 year back on irregular intake 
of T. carbamazepine 1 tds. Her EEG was abnormal and CT shows calcified granuloma.  
LSCS done for previous LSCS with oligohydramnios. Baby birth weight was 2.5kg    
with normal Apgar.   
 
 
 
 
AGE DISTRIBUTION
19%
55%
7%
19%
Upto 20 yrs 21 - 25 yrs 26 - 30 yrs > 30 yrs
RESULTS  AND  ANALYSIS 
 
Table 1: Age Distribution 
 
 
   * Majority of patient 42/ 75 (56%) belong to 21- 25 years of age group with mean age 
of 24.1 years 
   
 
 
 
 
Cases Age 
(In years) No % 
Up to 20 years 14 18.7 
21-25 years 42 56 
26-30 years 14 18.7 
> 30 years 5 6.7 
Total 75 100 
Range 18-33 years 
Mean 24.1 years 
S.D 3.6 years 
ANTENATAL CARE
88%
12%
BOOKED UNBOOKED
Table 2 : Antenatal Care 
Cases  
Antenatal Care No % 
Booked  66 88 
Unbooked  9 12 
Total 75 100 
 
   * Booked cases was 66/75 (88 %) and 9/ 75 (12%) of cases were unbooked  
 
 
 
 
 
 
 
 
 
 
 
 
 
PARITY
53%
47%
PRIMI MULTI
 
Table 3 : Parity 
 
Cases  
Parity No % 
Primi 40 53.3 
Multi 35 46.7 
Total 75 100 
 
• Out of 75 cases studied primigravida constitute 40 cases ( 53.3 % ) and 
multigravida constitute 35 cases 46.7 % 
 
 
 
 
 
 
 
 
 
 
 
DURATION OF DISEASE
45%
32%
3%
20%
2 - 5 yrs 6 - 10 yrs  10 - 15 yrs > 15 yrs
Table 4  : Duration of disease 
Cases  
Duration of disease 
(in years) No % 
0-1 years - - 
2 – 5 years 2 2.7 
6- 10 years 15 20 
10 – 15  years 34 45.3 
> 15 years 21 32 
Total 75 100 
Range 3 – 25 years 
Mean 13.4 years 
S.D 4.1 years 
 
• 45.3 % of cases had epilepsy for duration for 10 -15 years. 77% of patients had 
duration of disease more than 10 years . none of the patient had duration of disease 
of less than 1 year. 
 
 
 
Table 5 : Type of seizure 
Cases  
Type of seizure No % 
GTCS 74 98.7 
Partial 1 1.3 
Total 75 100 
 
* Out of 75 cases, 74 (98.7 %) had GTCS and only one case (1.3 %) had partial seizure 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISEASE FREE INTERVAL
21%
79%
0 - 9 months > 9 months
 
Table  6: Disease free interval 
Cases  
Disease free interval 
 
No % 
0 – 9 months 16 21.3 
> 9 months 59 78.7 
Total 75 100 
Range 2 days – 14 years 
Mean 5.1 years 
S.D 4.0 years 
 
* 16 cases out 75 (21.3%) had epileptic seizures during their antenatal period  
 
 
 
 
 
 
 
 
 
 
TYPE OF AED THERAPY
72%
3% 5%
7%
13%
MONOTHERAPY POLYTHERAPY IRREGULAR
DISCONTINUED NO THERAPY
Table 7 : Type of AED therapy 
 
Cases  
Type of therapy No % 
Mono therapy 54 72 
Polytherapy 5 6.7 
Irregular 10 13.3 
Discontinued 2 2.7 
Nil 4 5.3 
Total 75 100 
 
* Out of 75 cases studied of 54 cases (72%)  were on monotherapy and 5 cases( 6.7% ) 
were on  polytherapy. 13.3% had irregular intake of AED and 2.7% of cases discontinued 
the treatment after becoming pregnant. About 5.3% cases were not on any treatment as 
per neurologist advice.   
 
 
 
 
 
 
FOLIC ACID INTAKE
90%
3% 7%
YES IRREGULAR NO
 
Table 8 : Folic acid  intake 
Cases  
Folic acid intake No % 
Yes 68 90.7 
Irregular 2 2.7 
No 5 6.7 
Total 75 100 
 
• 68/ 75 (90.7 %) of epileptic women with pregnancy were on folic acid along with 
AED. 
• 2 women (2.7%) had irregular intake of folic acid and 5 women (6.7%) had no 
intake of folic acid.  
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Table 9 : EEG / CT Abnormalities 
Results 
Normal Abnormal 
 
Investigation 
No % No % 
EEG 23 30.7 52 69.3 
CT 66 88 9 12 
 
* Most of the women with epilepsy had abnormal EEG (69.3%) and normal CT (88%) 
   EEG was normal in 30.7% of cases while 12% had abnormal CT.  
 
 
 
 
 
 
 
 
 
 
 
 
GESTATIONAL AGE AT DELIVERY
15%
85%
PRETERM TERM
 
Table 10 : Gestational Age at delivery 
Cases  
Gestational Age at delivery 
(in weeks) 
No % 
< 34 weeks 2 2.7 
34 – 36 weeks 9 12 
> 37 weeks 64 85.3 
Preterm 11 14.7 
Term 64 85.3 
Total 75 100 
Range 32 – 42 weeks 
Mean 37.4 weeks 
S.D 1.9 weeks 
 
* Gestational age at delivery ranged from 32 – 42 weeks in our study 
 11/75 cases ( 14.7% ) had preterm delivery and 64/75cases (85.3 %) delivered at term. 
 
 
 
 
 
 
MODE OF DELIVERY
66%
28%
3%
3%
L N OUTLET ASSISTED BREECH LSCS
 
Table 11 : Mode of delivery 
Cases  
Mode of delivery No % 
Labour natural 50 66.7 
Outlet 2 2.7 
Assisted breech 2 2.7 
LSCS 21 28 
Total 75 100 
 
 * 50/ 75 (66.7 % ) of cases had normal delivery while 21/ 75 (28% )of cases underwent 
LSCS for various  indication. Assisted breech and outlet forceps delivery accounted for 
2.7% each. 
   
 
 
 
 
 
 
 
 
 
BIRTH WEIGHT
5%12% 17%
66%
< 2kgs 2 - 2.49 kgs 2.5 - 3 kgs > 3 kgs
Table 12 : Birth Weight 
Cases  
Birth Weight (in kgs) No % 
< 2 kgs 4 5.3 
2 - 2.49 kgs 13 17 
2.5  –  3 kgs 49 66 
> 3 kgs 9 12 
Total 75 100 
Low birth weight (<2.5 kgs) 17 22.3 
Term low birth weight 6 9.3 
Range 1.1 – 3.8 kgs 
Mean 2.65 kgs 
S.D 0.44 kgs 
 
* 49/75 (66 % ) of cases were of birth weight between 2.5 – 3 kg.  BW of less than 2.5 
kg accounted for17/ 75 ( 22.3%). Out of which term low birth weight constitute 6/75 
(9.3%). 
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Table 13 : Apgar Score 
At 1 minute At 5 minutes  
Apgar Score No % No % 
2 2 2.7 - - 
3 1 1.4 - - 
4 1 1.4 1 1.4 
5 - - 1 1.4 
6 70 94.6 2 2.7 
7 - - 1 1.4 
8 - - 69 93.2 
Total 74• 100 74• 100 
Range 2-6 4-8 
Mean 5.82 7.84 
S.D 0.77 0.66 
                     • One death 
* 70/75 (94.6%) of the babies had good 1 min Apgar and 69/75 (93.2%) of the babies had 
good 5 min Apgar score. 
Table 14 : Head Circumference 
 
Parameter 
 
Head Circumference (in cms) 
Range 30-35 cms 
Mean 33.5 cms 
S.D 1.1 cms 
 
* Average head circumference was 33.5 cms, with range of 30-35cms which was within 
normal limits. 
 
 
 
 
 
 
 
 
 
 
 
 
OBSTETRIC  COMPLICATIONS
36%
64%
PRESENT ABSENT
 
Table 15 : Obstetric Complications 
Cases  
Obstetric Complications No % 
IUD with Preterm 1 1.3 
IUGR 2 2.7 
Malpresentation 4 5.3 
Oligohydroamnios 2 2.7 
Oligo & IUGR 2 2.7 
Postdatism 6 8.0 
Pre term 8 11 
Preterm  &  Malpresentation 2 2.7 
Total cases with complications 27 36 
Cases without Complications 48 64 
                       Total 75 100 
 
* Out of 75 cases studied 48 cases (64%) had no complications and 27 cases (36%) had 
mentionable complications. 
 
 
 FREQUENCY OF SEIZURE
21%
79%
INCREASED NOT INCREASED
Table 16 : Frequency of seizures 
Cases  
Frequency of seizures No % 
Increased 16 21.3 
Not increased 59 78.7 
Total 75 100 
 
* Increase in frequency of seizures observed in 16/ 75 (21.3 %) of cases and there was no 
increase in 59/75 (78.7%) cases. 
 
 
 
 
 
 
 
Table 17 : Maternal Outcome 
Cases  
Maternal Outcome No % 
Good 75 100 
Poor Nil - 
Total 75 100 
 
• Maternal outcome was good in all cases (100%). 
Table 18 : Relationship between disease free interval and obstetric  
   complications 
Obst. Complications 
Present Absent 
 
Disease free interval 
No % No % 
0-1 years 7 33.3 14 66.7 
> 1 year 14 25.9 40 74.1 
Mean interval  5.77 years 4.84 years 
S.D 4.4 years 3.92 years 
‘p’ 0.3911  
Not Significant 
 
* There is no statistically significant correlation between the disease free interval and 
occurrence of obstetric complications. 
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Table 19 : Relationship between disease free interval and frequency of  
        seizures 
 
Frequency of seizures 
Increased Not increased 
 
Disease free 
interval 
No % No % 
0-1 years 16 76.2 5 23.8 
> 1 year - - 54 100 
Mean interval (in yrs) 0.29 years 6.41 years 
S.D 0.27 years 3.57 years 
‘p’ 0.0001  
Significant 
 
* There is statistically significant correlation between the disease free interval and 
frequency of seizures. 
DISCUSSION 
Epilepsy is the second common chronic neurological disorder complicating 
pregnancy. Pregnancy in a mother with epilepsy brings about several concerns including 
the risk of recurrent seizures, seizure aggravation, increased obstetric risks and increased 
adverse neonatal outcome. 
Review of literature shows vast majority of cases are uncomplicated but there are 
increased obstetric risks and increased adverse neonatal outcome when compared to 
general population. We made a prospective study comprising 75 women with epilepsy 
complicating pregnancy to assess the maternal and fetal outcome and occurrence of 
seizure frequency in mother.  
  In our study the age of the patients ranged from 18-33 years and mean 
maternal age was 24.1 years. The age group in our study is nearly comparable with the 
study conducted by (Thomas SV et al., 2001)16 in which the maternal age range was from 
19-38 years with mean age of 26. 
 In our study 53.3% of cases were primigravida and 46.7% of cases were 
multigravida whereas in the study by (Goel et al., 2006)9 the majority of the case was of 
multigravida 70.2%.  Most of the cases in our study are booked cases (88%). 
 
The duration of epilepsy for more than 10 years accounted for 77% of cases in 
our study while in the study conducted by (Goel et al., 2006)9, 72 % of the cases had 
duration of epilepsy for less than 10 years. There were no cases with duration of 
epilepsy for less than 1 year in our study. 
  Regarding the types of seizures, (Thomas et al., 2001)16 observed, 59.38% had 
GTCS and 40.37% of other types. (Chattopadhyay et al., 2008)5 in his study observed 56 
% of GTCS and 44 % of other types. In our study majority of the cases were of GTCS 
type (98.7%) and only one case (1.3%) had partial seizures. 
In our study  54 cases (72%) of patients were on monotherapy with 46 cases 
(61%) were on carbamazepine and 8 cases (10.6%) were on phenytoin. 6.7% of the 
patients were on polytherapy ( combination of carbamazepine and phenytoin- 3 cases , 
carbamazepine and clobazam – 7 cases , phenytoin and lamotrigine – 1 case)  , 13.3% 
were on irregular treatment and 2 cases (2.7 %) discontinued AED after becoming 
pregnant. In the study conducted by (Thomas SV et al., 2001)16 87.5% of cases were on 
monotherapy and 12% of cases were on polytherapy. 
About 90.7% of patients on epileptic drug were on regular intake of folic acid 
and 2.7 % were on irregular intake, while 6.7 % did not have any drug intake in our 
study. According to (Thomas SV et al., 2001)16 regular consumption of folic acid was 
documented in only in 40% of patients. In our study majority of cases were on regular 
folic acid intake. 
Premature delivery had been reported by (Chattopadhyay et al., 2008) 5 for 18.6% 
and (Goel et al., 2006)9 for 21.6% among their patients. In our study 14.7% delivered 
prematurely and 85.3 % cases delivered at term.  It shows there is slight increase 
incidence of prematurity in epileptic women. 
In our study, 66.7 % of cases had normal delivery while 28% of cases 
underwent LSCS for various indications including failed induction, fetal distress, 
oligohydroamnios, IUGR and postcaesarean pregnancy with associated 
complications.  Assisted breech and outlet forceps delivery accounted for 2.7% each.  
Mode of delivery in epileptic women is nearly comparable to study of (Goel et al., 2006)9, 
who observed normal vaginal delivery in 62% of cases and LSCS in 27% and instrumental 
delivery of 10.8%.   
While (Thomas SV et.al 2001) 16 and (Chattopadhyay et al., 2008)5 in their studies 
had more number of women undergoing LSCS accounting for 40.6% and 65.1% 
respectively. (Thomas SV et al., 2001)16 had mentioned fetal distress, failed induction and 
uterine inertia as indication for LSCS. 
 Birth weight of neonates range from 1.1 -3.8 kg with mean birth weight of 
2.65 kg. in our study. 5.5% of our babies had birth asphyxia (Apgar 1’= 2-6, 5’= 3-7). 
In (Thomas SV et al., 2001)16 study the birth weight ranges from 1.8- 4.0 kg with mean 
weight of 2.84 kg. 10.7% of babies had birth asphyxia (Apgar 1’ = 2-6,   5’= 3-7). 
Birth weight of less than 2.5 kg accounted for 22.3% in our study.  Similarly 
(Chattopadhyay et al., 2008)5 has reported 23.3% and (Goel et al., 2006)9 has reported 
18% of low birth weight babies. (Thomas SV et al., 2001)16  has reported 21 % of term 
low birth weight babies. In our study term low birth weight constitute only 9.3%. 
Average head circumference was 33.5 cms, with range of 30-35cms which was 
within normal limits in our study. It was similar to (Thomas SV et al., 2001) 16 study 
where there was average head circumference of 35 cms, with range of 32- 44cms. There 
was no cases of microcephaly in our study. 
Except for one fetus with congenital diaphragmatic hernia, whose mother was 
on phenytoin, there was no other congenital anomalies like neural tube, craniofacial, 
digital, cardiac/ urogenital defects in fetus of our epileptic women. (Thomas SV., 
2011) 17 has mentioned in his study that GIT anomalies like esophageal atresia, 
omphalocele, hernia (diaphragmatic, inguinal and umbilical) can occur in women with 
AED.  
In our study out of 75 cases, there were (5.3%) 4 cases of IUGR, (5.3%) 4 cases 
of oligohydramnios, (8%) 6 cases of malpresentation, (8%) 6 cases of postdatism. 
Preterm cases accounted for 14.7% (11 cases). There was one case of intrauterine 
death. Induction of labour was done in 14 cases (18.7%).  
(Goel et al., 2006) 9  has reported PIH (24.3%), abruption (5.4%), GDM (2.7%) and 
induction of labour in (18.9) % of cases in his study. Induction of labour was similar in 
our study, but there was no case of abruptio placenta, PIH or gestational diabetes. 
(Thomas SV et al., 2001)16 observed over quarter of patients with PIH, 
preeclampsia, IUGR, postdatism, placental previa and hydraminos. (Chattopadhyay et al., 
2008) 5 in observed IUGR (9.3 %) and preterm labour in (9.3%) of cases and there was no 
case of abruptio placenta, placenta previa, PIH or gestational diabetes. Type and 
occurrence of obstetric complications appear variable in different studies. 
Seizure frequency was increased in 21.3% of our cases and not increased in 
78.7% of cases. (Thomas et al., 2001)16 in his study noted an increase in seizure 
frequency in 12.5% and no change in 78.1% of cases which is in accordance with our 
study. 
 One important outcome noted in our study is, there exist statistically 
significant correlation between the disease free interval and frequency of seizures, 
with a ‘p’ value of 0.0001 (Table 19).  There was increased seizure frequency in 76.2% 
of cases with disease free interval of less than one year and there was no increase in 
seizure occurrence in which the disease free interval is more than one year.  
There is no statistically significant correlation between the disease free 
interval and occurrence of obstetric complications (P > 0.05) (Table 18). 
SUMMARY 
 75 epileptic women with pregnancy were assessed for maternal and fetal outcome  
including outcome of seizure frequency. 
 Mean maternal age was 24.1 years. 
 53.3%  were primigravida and 46.7% were multigravida. 
 77% had epilepsy for more than 10 years. 
 98.7% of patients had generalized tonic clonic seizures  and 1.3% had partial 
seizures. 
 72 % of patients were on monotherapy and 6.7% of patients were 
 on polytherapy. 
 90.7% of patients on antiepileptic drugs had regular intake of folic acid. 
 85.3% had term deliveries  and 14.7% had preterm deliveries. 
 66.7% had normal delivery and 28% underwent caesarean  sections for various 
obstetric indication. 
 Low birth weight babies (< 2.5 kg) were seen in23.3% of patients. No cases of 
microcephaly were observed in our study and all babies had normal head 
circumference. 
 Incidence of congenital anomalies was almost nil, except for one fetus with 
congenital diaphragmatic hernia. 
 None of the patients had any significant obstetric complications.  
 Seizure frequency was increased in 21.3%. 
 There was a significant correlation between disease free interval and increase in 
seizure frequency. Shorter the disease interval higher the incidence of seizure 
frequency. 76.2 % of cases with disease free interval  of less than one year had 
increased seizure frequency.  
 
   
CONCLUSION 
 
    The maternal and fetal outcome was good in our study among the pregnant 
women with epilepsy, except for few complications like prematurity and low birth weight 
which has slightly increased.   
The good maternal and fetal outcome with reduced occurrence of obstetric 
complications and reduced incidence of congenital anomalies in our study may be due to 
early booking, regular antenatal care, regular intake of anti epileptic drugs (preferentially 
monotherapy) and regular intake of folic acid along with antiepileptic drugs, which was 
found in most of our cases.  
There is increased frequency of seizures in one fifth of our pregnant epileptic 
women with statistically significant correlation between the disease free interval and 
frequency of seizures. Shorter the disease interval higher the incidence of seizure 
frequency.  Increased seizure frequency should be anticipated in patients with shorter 
disease free interval and may be advised to have regular antiepileptic drug intake and 
more frequent antenatal visits. 
There exists no statistically significant correlation between the disease free 
interval and occurrence of obstetric complications. 
Pregnant patients with epilepsy has  to be considered as high risk pregnancy which 
need evaluation, specialist opinion and referral to tertiary care centres for better maternal 
and neonatal outcome. The maternal and fetal complications can be minimized by the 
close coordination between neurologist, obstetrician and the pediatrician. 
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PROFORMA 
 
 
 
NAME:     AGE:                        IP No:                      Obstetric Code: 
 
 
ADDRESS                                Booked / Unbooked                                  LMP: 
 
                                                     
DOA:                                        DOD:                                                          EDD: 
 
 
COMPLAINTS:                                                           PAST HISTORY:  
 
Seizures       -                                             SEIZURES:  
 
Labour pain       -                                                        *  Age of onset              -    
 
Draining P/V       -                                                       *  Type                           -     GTCS /   PARTIAL 
                                                                                         
Bleeding P/V       -                                                       *  Disease free interval   -                                                      
 
Fetal movements   -                                              ANTIEPILEPTIC DRUG   
                                                       
FH        -                                                        *  Drug and dose        :                                        
     
Edema legs       -                                                        *  Duration of intake  :   
                                                 
Headache       -                                                        *  Regular / irregular  :            
 
Nausea       -                                               FOLIC ACID INTAKE    -          Y   /   N 
 
Vomiting       -                                               INVESTIGATIONS         -         EEG / CT 
                                     
Epigastric pain      -                                                Status epilepticus - 
        
Oliguria          -                                                Previous child drug effect -  
   
                                                                               HT   /  DM   /  PIH   /   TB  /  Renal disease 
          
 
EXAMINATIONS: 
 
 
 
 Consciousness:      C / SC / UC                                P/A :    Fundal  Height -     
 
 Obeying commands:   Y / N                                                        I Pelvic grip     -                                                      
 
 Temperature:               F / AF                                                      FH                    -                                                
 
 Anemia:      Y / N                              
 
 Edema legs:       Y / N                                           
 
 Pulse:     / min     BP:        mm/hg                           P/V:    Cervix effacement - 
 
  CVS:                                                                                            Dilatation      -  
                                                                                                             
  RS:                                                                                               Position        - 
                                                                                   
  CNS:     EOM                                                                              Membrane    - 
                 
                PERL                                                                             Pelvis            -                                         
 
                Limb movements                                                                                      
  
                DTR / Plantar reflex  
 
                Meningeal signs    
 
 
Optic Fundus:      
 
Neuro Opinion: 
                                                   
 
                                                                              
INVESTIGATIONS:       
 
                                  
 
       Blood Hb %             -                                                  LFT :                                              
 
      Urine       Alb            -                                            Blood Platelet count -                                            
           Sugar         -                                                 
           Deposit      -                                                 USG  -  GA / AFI/ ANOMALIES 
                                                                                              
      Blood:     Urea    -                                                    
           Sugar        -                                                 EEG:     N / Ab                                    
 
      Serum:    Creatinine  -                                                CT :      N / Ab       
                     Uric acid     -  
       
Serum electrolytes           -  
 
 
                                                                    
LABOUR: 
 
            Spontaneous   /   Induced    -            
            Mode of Delivery:       Vaginal / Instrumental / LSCS                                                                                                                 
            Indication: 
            Complications: 
 
FETAL OUTCOME 
           Birth weight  -  
           Apgar  score  - 
           Anomalies      - 
           Head circumference - 
           IUD / Still Birth – 
 
 
 
MASTER CHART 
 
Seizures Drugs intake  Investigations Delivery Fetal   outcome  Maternal  outcome  
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1 25 4722 YES PRIMI 13 GTCS 11      POLY YES AB NORMAL 36 LN 2.4 6 8 33 Nil      Preterm No increase GOOD 
2 26 4893 YES MULTI 7 GTCS 0.5 MONO YES AB NORMAL 37 LSCS 3.5 6 8 33 Nil Mal.pres Increase GOOD 
3 21 48424 YES MULTI 9 GTCS 10 MONO YES N NORMAL 38 LSCS 2.5 6 8 34 Nil Oligo No increase GOOD 
4 20 48158 NO MULTI 7 GTCS 13 MONO YES N NORMAL 38 LN 2.7 6 8 33 Nil Nil No increase GOOD 
5 25 48396 YES PRIMI 12 GTCS 13 IRREG. YES N NORMAL 41 LSCS 2.3 6 8 33 Nil Post datism No increase GOOD 
6 25 9998 YES PRIMI 13 GTCS 0.17 MONO YES N NORMAL 38 LSCS 3 6 8 33 Nil Nil Increase GOOD 
7 23 9995 YES MULTI 20 GTCS 0.4 POLY YES AB CG 38 LSCS 2.8 6 8 34 Nil Nil Increase GOOD 
8 23 9032 YES MULTI 12 GTCS 12 MONO YES N NORMAL 37 LN 2.5 6 8 33 Nil Nil No increase GOOD 
9 23 9690 NO PRIMI 16 GTCS 0.33 IRREG. IRREG. AB NORMAL 38 LN 2.3 6 8 34 Nil Nil Increase GOOD 
10 23 9135 YES MULTI 12 GTCS 11 MONO YES N NORMAL 37 LSCS 3 6 7 33 Nil Mal.pres No increase GOOD 
11 19 8499 YES PRIMI 9 GTCS 0.5 MONO YES AB NORMAL 38 LN 2.8 6 8 33 Nil Nil Increase GOOD 
12 21 9361 YES PRIMI 5 GTCS 7 MONO YES AB NORMAL 41 LSCS 3 2 6 34 Nil Post datism No increase GOOD 
13 20 9418 YES PRIMI 6 GTCS 7 MONO YES AB CG 39 LN 2.8 6 8 33 Nil Nil No increase GOOD 
14 25 8628 YES MULTI 10 GTCS 0.5 IRREG. YES AB NORMAL 38 Outlet 2.5 6 8 33 Nil Nil Increase GOOD 
15 21 8286 YES PRIMI 9 GTCS 12 MONO YES AB CG 37 LN 2.5 6 8 34 Nil Nil No increase GOOD 
16 32 8243 YES PRIMI 20 GTCS 4 MONO YES AB NORMAL 38 LN 3 6 8 33 Nil Nil No increase GOOD 
17 33 7053 YES PRIMI 13 GTCS 14 IRREG. IRREG AB NORMAL 38 LN 2.5 6 8 34 Nil Nil No increase GOOD 
18 22 6629 YES MULTI 9 GTCS 3 POLY YES N NORMAL 38 LSCS 2.5 6 8 35 Nil Nil No increase GOOD 
19 25 7402 YES PRIMI 15 GTCS 0.009 IRREG. YES AB NORMAL 38 LSCS 2.2 6 8 33 Nil Oligo, IUGR Increase GOOD 
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20 18 11491 YES PRIMI 15 GTCS 3 MONO YES N NORMAL 38 LSCS 2.3 6 8 33 Nil Nil No increase GOOD 
21 29 10081 YES MULTI 13 GTCS 0.67 MONO YES AB NORMAL 34 LN 2.2 6 8 32 Nil PRE TERM Increase GOOD 
22 30 1841 NO MULTI 14 GTCS 0.006 NIL YES AB NORMAL 38 LSCS 2.7 6 8 34 Nil Mal.pres Increase GOOD 
23 26 1796 YES MULTI 8 GTCS 0.33 POLY YES AB NORMAL 37 LN 2.7 6 8 35 Nil Nil Increase GOOD 
24 21 1023 YES MULTI 7 GTCS 4 MONO YES AB NORMAL 35 ABD 2.4 6 8 35 Nil 
PRE TERM 
Mal.pres No increase GOOD 
25 25 1338 NO MULTI 9 GTCS 11 MONO YES N NORMAL 39 LN 2 6 8 33 Nil IUGR No increase GOOD 
26 19 10518 YES PRIMI 10 GTCS 0.33 MONO YES AB NORMAL 38 LN 3.2 6 8 34 Nil Nil Increase GOOD 
27 28 10547 YES MULTI 18 GTCS 6 IRREG. YES AB CG 37 LSCS 2.5 6 8 33 Nil OLIGO No increase GOOD 
28 23 1165 YES MULTI 14 GTCS 0.6 MONO YES AB NORMAL 38 LSCS 3 6 8 35 Nil Nil Increase GOOD 
29 21 1090 YES PRIMI 13 GTCS 3 MONO YES AB NORMAL 36 LN 2.3 2 4 33 
Cong.dia
ph.hernia PRE TERM No increase GOOD 
30 25 2970 YES PRIMI 11 GTCS 10 MONO YES N NORMAL 37 LSCS 3.1 6 8 35 Nil Nil No increase GOOD 
31 23 2403 YES MULTI 11 GTCS 6 MONO YES AB CG 39 LSCS 2.5 6 8 33 Nil Nil No increase GOOD 
32 26 2935 YES PRIMI 10 GTCS 3 MONO YES N NORMAL 37 LN 3.3 6 8 34 Nil Nil No increase GOOD 
33 24 3149 YES MULTI 9 GTCS 3 MONO YES AB NORMAL 38 LSCS 2.7 6 8 33 Nil Nil No increase GOOD 
34 25 57942 YES MULTI 7 GTCS 2 MONO YES AB NORMAL 37 LN 2.8 6 8 35 Nil Nil No increase GOOD 
35 20 57508 YES PRIMI 12 GTCS 11 MONO YES AB NORMAL 37 LN 2.5 6 8 33 Nil Nil No increase GOOD 
36 25 66069 YES PRIMI 11 GTCS 9 MONO YES AB NORMAL 34 LN 2.1 6 8 32 Nil PRE TERM No increase GOOD 
37 20 6073 NO PRIMI 10 GTCS 9 IRREG. YES N NORMAL 34 LN 2 6 8 31 Nil PRE TERM No increase GOOD 
38 23 61299 YES MULTI 7 GTCS 0.17 MONO YES AB CG 37 LN 3.8 6 8 33 Nil Nil Increase GOOD 
39 25 9242 NO MULTI 8 GTCS 1 MONO YES AB NORMAL 34 LN 1.8 Dead Dead Dead Nil PRE TERM No increase GOOD 
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IUD 
40 32 59639 YES MULTI 7 GTCS 3 MONO YES AB NORMAL 34 LN 2 6 8 32 Nil PRE TERM No increase GOOD 
41 20 8016 YES PRIMI 9 GTCS 6 MONO YES AB CG 32 ABD 1.6 4 6 30 Nil 
  PRE TERM   
    Mal.pres No increase GOOD 
42 23 6362 YES MULTI 9 GTCS 4 MONO YES AB NORMAL 37 LN 2.5 6 8 33 Nil Nil No increase GOOD 
43 20 55177 YES PRIMI 13 GTCS 7 IRREG. YES AB NORMAL 37 LN 2.5 6 8 33 Nil Nil No increase GOOD 
44 23 5220 YES MULTI 9 GTCS 6 MONO YES AB NORMAL 37 LN 3 6 8 33 Nil Nil No increase GOOD 
45 29 5013 YES MULTI 12 GTCS 9 MONO YES AB NORMAL 37 LN 3 6 8 33 Nil Nil No increase GOOD 
46 20 1863 YES PRIMI 7 GTCS 0.08 DISCONT. NO AB NORMAL 38 LN 3.1 6 8 35 Nil Nil Increase GOOD 
47 23 7075 YES MULTI 7 GTCS 6 MONO YES AB NORMAL 39 LN 3 6 8 35 Nil Nil No increase GOOD 
48 23 2590 YES MULTI 5 GTCS 0.006 MONO YES AB NORMAL 38 LN 3.2 6 8 34 Nil Nil Increase GOOD 
49 29 1936 YES MULTI 5 GTCS 5 MONO YES N NORMAL     42 LN 2.7 6 8 33 Nil Postdatism No increase GOOD 
50 30 2098 YES MULTI 18 GTCS 11 MONO YES AB CG 37 LN 2.7 6 8 34 Nil Nil No increase GOOD 
51 28 3678 YES MULTI 8 GTCS 8 MONO YES AB NORMAL 38 LN 2.7 6 8 33 Nil Nil No increase GOOD 
52 21 2549 YES PRIMI 9 GTCS 4 IRREG. YES AB NORMAL 37 LN 2.8 6 8 35 Nil Nil No increase GOOD 
53 33 14151 YES MULTI 13 GTCS 6 MONO YES N NORMAL 38 LN 2.9 6 8 35 Nil Nil No increase GOOD 
54 21 12675 YES PRIMI 12 GTCS 8 MONO YES AB NORMAL 41 LN 2.7 6 8 34 Nil Postdatism No increase GOOD 
55 23      7810 YES PRIMI 9 GTCS 2 MONO YES AB NORMAL 37 LN 2.8 6 8 34 Nil Nil No increase GOOD 
56 23 7429 YES MULTI 13 GTCS 3 MONO YES N NORMAL 37 LN 2.7 6 8 35 Nil Nil No increase GOOD 
57 31 9548 YES MULTI 12 GTCS 1 MONO YES AB NORMAL 38 LSCS 2.8 6 8 34 Nil Nil No increase GOOD 
58 20 7989 NO PRIMI 8 GTCS 8 MONO YES N NORMAL 37 LN 2.7 6 8 34 Nil Nil No increase GOOD 
59 22 52829 YES PRIMI 11 GTCS 3 IRREG. YES AB NORMAL 41 LN 2.8 6 8 33 Nil Postdatism No increase GOOD 
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60 26 10535 YES PRIMI 12 GTCS 0.03 MONO YES AB NORMAL 39 LN 2.8 6 8 34 Nil Nil Increase GOOD 
61 20 7985 YES PRIMI 9 GTCS 9 MONO YES N NORMAL 37 LSCS 2.7 6 8 34 Nil OLIGO, IUGR No increase GOOD 
62 19 9631 YES PRIMI 7 GTCS 1 MONO YES N NORMAL 34 LN 1.8 6 8 31 Nil PRETERM No increase GOOD 
63 25 6055 YES PRIMI 8 GTCS 0.9 MONO YES AB NORMAL 32 LN 1.1 3 5 30 Nil PRETERM No increase GOOD 
64 25 5384 YES PRIMI 9 GTCS 9 NIL NO N NORMAL 37 LSCS 3 6 8 34 Nil Nil No increase GOOD 
65 30 65225 YES MULTI 13 GTCS 2 POLY YES AB CG 39 LN 3.5 6 8 35 Nil Nil No increase GOOD 
66 24 7902 NO PRIMI 12 GTCS 1 MONO YES N NORMAL 38 LN 2.6 6 8 32 Nil Nil No increase GOOD 
67 28 47515 YES PRIMI 8 GTCS 4 MONO YES N NORMAL 41 Outlet 2.8 6 8 34 Nil Postdatism No increase GOOD 
68 25 47439 YES PRIMI 12 GTCS 9 NIL NO N NORMAL 37 LN 2.5 6 8 33 Nil Nil No increase GOOD 
69 25 46396 YES PRIMI 13 GTCS 10 NIL NO AB NORMAL 37 LSCS 2.3 6 8 33 Nil IUGR No increase GOOD 
70 21 48421 YES MULTI 11 GTCS 7 MONO YES AB NORMAL 37 LN 2.7 6 8 34 Nil Nil No increase GOOD 
71 23 5215 YES MULTI 13 Partial 6 MONO YES AB NORMAL 39 LN 2.8 6 8 33 Nil Nil No increase GOOD 
72 24 2978 NO PRIMI 13 GTCS 5 MONO YES AB NORMAL 37 LN 2.9 6 8 34 Nil Nil No increase GOOD 
73 20 91840 YES PRIMI 12 GTCS 4 MONO YES AB NORMAL 38 LN 2.7 6 8 33 Nil Nil No increase GOOD 
74 25 1400 YES PRIMI 13 GTCS 6 MONO YES N NORMAL 37 LN 2.6 6 8 34 Nil Nil No increase GOOD 
75 26 10571 YES PRIMI 10 GTCS 6 DISCONT. NO AB NORMAL 38 LSCS 3.5 6 8 35 Nil Nil No increase GOOD 
 
 
 
